第一单位：
Taiho Pharmaceutical Co. Ltd., Tsukuba, Japan. isao-miyazaki@taiho.co.jp.
作者：
Isao,Miyazaki [1]
;
Igor,Odintsov [2]
;
Keiji,Ishida [3]
;
Allan J W,Lui [4]
;
Masanori,Kato [3]
;
Tatsuya,Suzuki [3]
;
Tom,Zhang [5]
;
Kentaro,Wakayama [3]
;
Renate I,Kurth [5]
;
Ryan,Cheng [5]
;
Hidenori,Fujita [3]
;
Lukas,Delasos [6]
;
Morana,Vojnic [7]
;
Inna,Khodos [8]
;
Yukari,Yamada [3]
;
Kota,Ishizawa [9]
;
Marissa S,Mattar [5]
;
Kaoru,Funabashi [3]
;
Qing,Chang [8]
;
Shuichi,Ohkubo [3]
;
Wakako,Yano [3]
;
Ryuichiro,Terada [3]
;
Claudio,Giuliano [10]
;
Yue Christine,Lu [5]
;
Annalisa,Bonifacio [10]
;
Siddharth,Kunte [11]
;
Monika A,Davare [12]
;
Emily H,Cheng [13]
;
Elisa,de Stanchina [8]
;
Emanuela,Lovati [10]
;
Yoshikazu,Iwasawa [3]
;
Marc,Ladanyi [14]
;
Romel,Somwar [15]
作者单位：
Taiho Pharmaceutical Co. Ltd., Tsukuba, Japan. isao-miyazaki@taiho.co.jp.
[1]
Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.;Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.;Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
[2]
Taiho Pharmaceutical Co. Ltd., Tsukuba, Japan.
[3]
Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.;Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK.
[4]
Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
[5]
Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.;Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA.
[6]
Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.;Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.;Northwell Health Cancer Institute, Lenox Hill Hospital, New York, NY, USA.
[7]
Antitumor Assessment Core Facility, Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
[8]
Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.;Department of Education and Support for Regional Medicine, Tohoku University Hospital, Sendai, Japan.
[9]
Helsinn Healthcare SA, Lugano, Switzerland.
[10]
Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.;Dana Cancer Center, Toledo, OH, USA.
[11]
Department of Pediatrics, Oregon Health Sciences University, Portland, OR, USA.
[12]
Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
[13]
Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.;Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
[14]
Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. somwarr@mskcc.org.;Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. somwarr@mskcc.org.
[15]
DOI
10.1038/s43018-023-00663-3
PMID
37814012
发布时间
2023-10-27
换一批
